NASDAQ$NAMS
NewAmsterdam Pharma Company NV · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M and an operating loss of $58.4M.
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0 million versus $3.0 million, with operating loss of $58.4 million compared with $68.9 million as R&D spend moderated slightly. The company remains clinical-stage, advancing obicetrapib and related cardiometabolic programs.
- Revenue $3.0M from collaboration/licensing.
- Operating loss $58.4M; R&D $38.0M.
- Pipeline focused on LDL-C lowering and cardiovascular outcomes.
- Cash and partnership funding support runway.
- No product sales yet.
Headline financials
Revenue & EPS history
NewAmsterdam Pharma · Revenue · Quarterly
$3.04M
Forward guidance
Clinical-stage biotech without product revenue guidance; catalysts are trial readouts and regulatory interactions.
Tailwinds
- Operating loss improved modestly YoY.
- Partnership economics on obicetrapib.
- Large addressable market in LDL management.
Headwinds
- No commercial revenue.
- Trial and regulatory risk.
- Substantial ongoing cash burn.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2026
+0.8%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.6%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+18.2%
Q3 2024
Best reaction
-9.6%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +25.4% | +1.5% | |
| Q4 2025 | -3.0% | +2.6% | -17.9% | |
| Q3 2025 | +4.3% | +6.7% | -3.5% | |
| Q1 2025 | +1.2% | -8.3% | -3.2% | |
| Q4 2024 | +10.2% | +13.4% | +21.7% | |
| Q3 2024 | +18.2% | +28.4% | -4.2% | |
| Q1 2024 | -9.6% | -12.1% | -7.8% | |
| Q2 2023 | -5.7% | -4.9% | -2.4% | |
| Q4 2023 | -5.7% | -4.9% | -2.4% | |
| Q1 2023 | +0.3% | +2.0% | -0.9% | |
| Q4 2022 | +2.1% | +1.7% | +7.4% | |
| Q3 2022 | -0.1% | +0.1% | +0.8% | |
| Q2 2022 | +0.1% | +0.1% | +0.4% | |
| Q1 2022 | +0.0% | +0.1% | +0.3% | |
| Q3 2021 | -0.3% | +0.2% | -0.1% | |
| Q2 2021 | +0.2% | +0.2% | -1.2% | |
| Q1 2021 | +0.1% | +0.2% | +1.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro